Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 14/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 13/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 13/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3953362 | 0.95 | OPRM1 (0.43) | OPRM1OPRL1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL2989048 | 0.90 | OPRM1 (0.44) | OPRM1OPRL1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL3959432 | 0.80 | OPRM1 (0.40) | OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL2986994 | 0.79 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL31568823 | 0.77 | CHRNB4 (0.55) | OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL5187982 | 0.77 | CHRNB4 (0.55) | OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL13403254 | 0.77 | CHRNB4 (0.55) | OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL3538855 | 0.77 | CHRNB4 (0.55) | OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL3538856 | 0.77 | CHRNB4 (0.55) | OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL11463527 | 0.75 | OPRL1 (0.68) | OPRM1OPRL1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101573113-A | Derivatives of pyridine, indolizine and quinolizine, preparation thereof and therapeutic use thereof | SANOFI AVENTIS (FR) | 2009-11-04 | — | — | CN | claimed |
| EP-2077837-A2 | DERIVATIVES OF PYRROLIZINE, INDOLIZINE AND QUINOLIZINE, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2009-07-15 | — | — | EP | claimed |
| WO-2008037881-A2 | DERIVATIVES OF PYRROLIZINE, INDOLIZINE AND QUINOLIZINE, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-04-03 | — | — | WO | claimed |
| US-20100267766-A1 | DERIVATIVES OF PYRROLIZINE, INDOLIZINE AND QUINOLIZINE, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-10-21 | — | — | US | disclosed |
| US-7776880-B2 | Derivatives of pyrrolizine, indolizine and quinolizine, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-08-17 | — | — | US | disclosed |
| CN-101573113-A | Derivatives of pyridine, indolizine and quinolizine, preparation thereof and therapeutic use thereof | SANOFI AVENTIS (FR) | 2009-11-04 | — | — | CN | disclosed |
| US-20090258899-A1 | DERIVATIVES OF PYRROLIZINE, INDOLIZINE AND QUINOLIZINE, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-10-15 | — | — | US | disclosed |
| EP-2077837-A2 | DERIVATIVES OF PYRROLIZINE, INDOLIZINE AND QUINOLIZINE, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008037881-A2 | DERIVATIVES OF PYRROLIZINE, INDOLIZINE AND QUINOLIZINE, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258899-A1 | DERIVATIVES OF PYRROLIZINE, INDOLIZINE AND QUINOLIZINE, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INMT, IDO1, NQO2 | OPRM1 154/4885OPRL1 647/4885OPRD1 233/4885 |
| US-20100267766-A1 | DERIVATIVES OF PYRROLIZINE, INDOLIZINE AND QUINOLIZINE, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INMT, IDO1, NQO2 | OPRM1 154/4885OPRL1 647/4885OPRD1 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.